X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs IPCA LABS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA IPCA LABS TORRENT PHARMA/
IPCA LABS
 
P/E (TTM) x 45.0 28.1 159.8% View Chart
P/BV x 6.1 3.6 170.6% View Chart
Dividend Yield % 0.8 0.1 640.0%  

Financials

 TORRENT PHARMA   IPCA LABS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
IPCA LABS
Mar-18
TORRENT PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,550695 222.9%   
Low Rs1,144400 285.9%   
Sales per share (Unadj.) Rs354.7260.2 136.3%  
Earnings per share (Unadj.) Rs40.119.0 211.2%  
Cash flow per share (Unadj.) Rs64.233.1 194.3%  
Dividends per share (Unadj.) Rs14.001.00 1,400.0%  
Dividend yield (eoy) %1.00.2 569.4%  
Book value per share (Unadj.) Rs273.1213.0 128.2%  
Shares outstanding (eoy) m169.22126.20 134.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.82.1 180.4%   
Avg P/E ratio x33.628.9 116.4%  
P/CF ratio (eoy) x21.016.6 126.6%  
Price / Book Value ratio x4.92.6 191.8%  
Dividend payout %34.95.3 662.8%   
Avg Mkt Cap Rs m227,89769,120 329.7%   
No. of employees `00014.713.3 110.9%   
Total wages/salary Rs m11,3537,359 154.3%   
Avg. sales/employee Rs Th4,083.02,477.4 164.8%   
Avg. wages/employee Rs Th772.3555.2 139.1%   
Avg. net profit/employee Rs Th461.3180.6 255.4%   
INCOME DATA
Net Sales Rs m60,02132,836 182.8%  
Other income Rs m2,988418 714.9%   
Total revenues Rs m63,00933,254 189.5%   
Gross profit Rs m13,4934,505 299.5%  
Depreciation Rs m4,0861,777 229.9%   
Interest Rs m3,085240 1,284.3%   
Profit before tax Rs m9,3102,905 320.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529511 494.8%   
Profit after tax Rs m6,7812,394 283.2%  
Gross profit margin %22.513.7 163.9%  
Effective tax rate %27.217.6 154.4%   
Net profit margin %11.37.3 155.0%  
BALANCE SHEET DATA
Current assets Rs m52,62319,455 270.5%   
Current liabilities Rs m52,02210,076 516.3%   
Net working cap to sales %1.028.6 3.5%  
Current ratio x1.01.9 52.4%  
Inventory Days Days12098 122.2%  
Debtors Days Days7667 113.9%  
Net fixed assets Rs m85,01620,260 419.6%   
Share capital Rs m846252 335.3%   
"Free" reserves Rs m45,37626,633 170.4%   
Net worth Rs m46,22226,886 171.9%   
Long term debt Rs m41,1152,340 1,757.0%   
Total assets Rs m142,43241,173 345.9%  
Interest coverage x4.013.1 30.7%   
Debt to equity ratio x0.90.1 1,022.0%  
Sales to assets ratio x0.40.8 52.8%   
Return on assets %6.96.4 108.3%  
Return on equity %14.78.9 164.8%  
Return on capital %14.210.8 131.9%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m14,58015,642 93.2%   
Fx outflow Rs m3,6004,884 73.7%   
Net fx Rs m10,98010,759 102.1%   
CASH FLOW
From Operations Rs m8,9423,411 262.1%  
From Investments Rs m-47,070-1,354 3,476.3%  
From Financial Activity Rs m34,174-1,304 -2,620.5%  
Net Cashflow Rs m-3,655753 -485.3%  

Share Holding

Indian Promoters % 71.5 45.9 155.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.4 61.6%  
FIIs % 12.6 25.3 49.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.4 50.6%  
Shareholders   26,511 36,892 71.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SUN PHARMA  PFIZER  

Compare TORRENT PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 317 Points Higher; Realty and FMCG Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day on a strong note. Gains were largely seen in the realty sector and FMCG sector.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 19, 2018 03:35 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS